A Solid Tumor Study for Long Term Treatment of Cancer Patients Who Participated in Adagrasib Studies

NCT07415031 · tracked via the Priya Life Science UK tracker

Sponsor

Mirati Therapeutics Inc.

Phase

Phase 2

Started

2026-05-06

Last updated

2026-08-18

Condition(s) studied

Solid Tumors

Investigational drug(s) / intervention(s)

AdagrasibPembrolizumabCetuximabPemetrexedDocetaxelIrinotecanLeucovorinOxaliplatinFluorouracil

Adagrasib: Specified dose on specified days

Pembrolizumab: Specified dose on specified days

Cetuximab: Specified dose on specified days

Pemetrexed: Specified dose on specified days

Docetaxel: Specified dose on specified days

Irinotecan: Specified dose on specified days

Leucovorin: Specified dose on specified days

Oxaliplatin: Specified dose on specified days

Fluorouracil: Specified dose on specified days

Study summary

This is an open-label, solid tumor, continuation, rollover trial which enrolls participants from ongoing BMS parent studies that evaluated adagrasib (MRTX849, BMS-986503) either as monotherapy or in combination with other cancer therapies in patients with non-small cell lung cancer (NSCLC), colorectal cancer (CRC) and other advanced solid tumors.

Eligibility

Sex

ALL

Min age

18 Years

Max age

—

Healthy volunteers

Inclusion Criteria: * Participant is eligible to receive continued study treatment as per the parent study, and/or investigator assessed clinical benefit. * Individuals with assigned female sex at birth (AFSB) must have documented proof that they are not of childbearing potential. IOCBP participants who are sexually active must agree to follow the instructions for method(s) of contraception and included in the ICF. Exclusion Criteria: * Participant is not eligible for study treatment per the parent study eligibility criteria. * Participants who have completed treatment with the study drugs, progressed on prior study treatment, or discontinued study treatment due to toxicity in the parent study are not eligible to receive study drug in this study. * Participants not receiving clinical benefit from parent study drug as assessed by the investigator. Other protocol defined inclusion/exclusion criteria applies.

Primary outcome measure(s)

Number of Participants With Adverse Events (AEs) — Up to 90 days from last dose or study discontinuation
Number of Participants With AEs Leading to Treatment Discontinuation — Up to 90 days from last dose or study discontinuation
Number of Participants With Serious Adverse Events (SAEs) — Up to 90 days from last dose or study discontinuation
Number of Participants With AEs Leading to Death — Up to 90 days from last dose or study discontinuation

Trial sites (100)

Facility	City	Region	Status
Local Institution - 0005	Phoenix	Arizona	Withdrawn
Southern California Permanente Medical Group	Bellflower	California	Recruiting
Local Institution - 0082	Long Beach	California	Not Yet Recruiting
Local Institution - 0003	Newark	Delaware	Withdrawn
Florida Cancer Specialists - North	St. Petersburg	Florida	Recruiting
Local Institution - 0112	Wichita	Kansas	Not Yet Recruiting
Local Institution - 0092	Boston	Massachusetts	Withdrawn
Local Institution - 0080	Boston	Massachusetts	Not Yet Recruiting
Mayo Clinic in Rochester, Minnesota	Rochester	Minnesota	Recruiting
Metro-Minnesota Community Oncology Research Consortium (MMCORC)	Saint Paul	Minnesota	Recruiting
Nebraska Cancer Specialists	Omaha	Nebraska	Recruiting
Oncology Associates Of Oregon, Pc	Eugene	Oregon	Recruiting
The West Clinic, PLLC dba West Cancer Center	Germantown	Tennessee	Recruiting
Texas Oncology-Bedford	Bedford	Texas	Recruiting
Texas Oncology - Baylor Charles A. Sammons Cancer Center	Dallas	Texas	Recruiting
Texas Oncology - DFW	Grapevine	Texas	Recruiting
Local Institution - 0013	Bellingham	Washington	Not Yet Recruiting
Local Institution - 0093	St Leonards	New South Wales	Not Yet Recruiting
Local Institution - 0033	Ghent	Belgium	Not Yet Recruiting
Local Institution - 0072	Vancouver	British Columbia	Not Yet Recruiting
Local Institution - 0037	Beijing	Beijing Municipality	Not Yet Recruiting
Local Institution - 0045	Xiamen	Fujian	Not Yet Recruiting
Local Institution - 0042	Zhengzhou	Henan	Not Yet Recruiting
Local Institution - 0038	Changsha	Hunan	Not Yet Recruiting
Local Institution - 0046	Nanjing	Jiangsu	Not Yet Recruiting
Local Institution - 0048	Nanchang	Jiangxi	Not Yet Recruiting
Local Institution - 0049	Shenyang	Liaoning	Not Yet Recruiting
Local Institution - 0039	Jinan	Shandong	Not Yet Recruiting
Local Institution - 0047	Linyi	Shandong	Not Yet Recruiting
Local Institution - 0043	Shanghai	Shanghai Municipality	Not Yet Recruiting
Local Institution - 0040	Chengdu	Sichuan	Not Yet Recruiting
Local Institution - 0044	Hangzhou	Zhejiang	Not Yet Recruiting
Local Institution - 0041	Xi'an	China	Not Yet Recruiting
Local Institution - 0076	Nice	Alpes-Maritimes	Not Yet Recruiting
Local Institution - 0086	Nice	Alpes-Maritimes	Not Yet Recruiting
Local Institution - 0074	Strasbourg	Alsace	Not Yet Recruiting
Local Institution - 0103	Pessac	Aquitaine	Not Yet Recruiting
Local Institution - 0091	Besançon	Doubs	Not Yet Recruiting
Local Institution - 0065	La Tronche	Isère	Not Yet Recruiting
Local Institution - 0063	Saint-Herblain	Loire-Atlantique	Not Yet Recruiting

+ 60 more sites — see the full list on the official registry below.

Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT07415031 on ClinicalTrials.gov ↗ ← All trials in the UK